LONDON -- Markets have been weaker throughout Europe this morning, paring yesterday's gains as weaker-than-expected European confidence data added to fears surrounding the outcome of today's EU summit. So far the S&P 500
Despite these losses, there are a number of European stocks making some headway today, so here are three ADRs that may be on track to beat the S&P.
The Danish developer of obesity drugs climbed more than 3.5% in European trade, although this slipped a little as the morning went on. Novo Nordisk now sees opportunities in the U.S. for its diabetes drug, Victoza, which it is currently testing as an aid against obesity.
The French water utility company Veolia Environnement
The move comes as part of a broader effort by the company to reduce its debt to 3 billion euros by the end of next year, a goal CEO Antoine Frerot announced last month.
This comes after the CEO of rival firm GlaxoSmithKline
Despite the ongoing eurozone troubles, this morning's European trading did provide some winners -- and perhaps some European buying opportunities. Indeed, legendary investor Warren Buffett has recently spent more than $1 billion buying the stock of a prominent European large cap. If you want to know why Mr. Buffett has bought into Europe, this special Motley Fool report -- "The One UK Share That Warren Buffett Loves" -- reveals everything, including the price he paid. You can download the report today for free. But hurry -- the report is available for a limited time only.
The Motley Fool is helping Europe invest. Better. And with the eurozone economy so uncertain, we're urging everyone to read "Ten Steps To Making A Million In The Market." This report may transform your wealth. Click here now to request your free, no-obligation copy.
Further Motley Fool investment opportunities: